Showing results (361-370 of 533) with videos related to
Sort By:
Pageof 54
Neurology|April 22, 2022
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament LightSuzanne E Schindler, Thomas K Karikari, Nicholas J Ashton, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 12, 2020
Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learningNicolai Franzmeier, Nikolaos Koutsouleris, Tammie Benzinger, et al.Alzheimer'S Research & Therapy|July 31, 2015
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheterBrendan P Lucey, Celedon Gonzales, Ujjwas Das, et al.Nature Medicine|December 1, 2022
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoringNicholas J Ashton, Shorena Janelidze, Niklas Mattsson-Carlgren, et al.The Journal of Prevention of Alzheimer'S Disease|October 25, 2022
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task ForceD Angioni, J Delrieu, O Hansson, et al.Nature Medicine|November 24, 2022
CSF tau microtubule-binding region identifies pathological changes in primary tauopathiesKanta Horie, Nicolas R Barthélemy, Salvatore Spina, et al.Annals of Neurology|June 7, 2022
Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid AngiopathyZahra Shirzadi, Wai-Ying W Yau, Stephanie A Schultz, et al.Neurology|September 3, 2020
Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional studyJingqin Luo, Folasade Agboola, Elizabeth Grant, et al.Journal of Alzheimer'S Disease : JAD|July 24, 2022
Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based ApproachJigyasha Timsina, Duber Gomez-Fonseca, Lihua Wang, et al.The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.Pageof 54